Vertex's Endocrinology Play: A New Growth Engine? Vertex Pharmaceuticals' acquisition of Crinetics has generated significant excitement in the biotech community.
The deal gives Vertex immediate access to the lucrative endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise, with an estimated value of roughly $10 billion.
One of the most significant benefits of the acquisition is Palsonify (paltusotine), an oral treatment for acromegaly that has already received regulatory approval in Europe.